A randomized phase II/III study of the CSF-470 therapeutic vaccine plus BCG plus rhGM-CSF versus IFN-α2b in high risk cutaneous melanoma patients in the stages IIB, IIC and III
Adjuvant treatment of high-risk cutaneous melanoma (CM) patients (pts) is still

